ALX Oncology Holdings Inc

NASDAQ:ALXOUnited States

ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. Its product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. Cancer cells leverage CD47, a cell surface protein, as a don’t eat me signal to evade macrophage phagocytosis or as a don't activate T-cells signal that prevents activation of T-cells by dendritic cells. It focuses on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. It also has a preclinical program focused on developing ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer.

Contact Information

Headquarters

323 Allerton AvenueSOUTH SAN FRANCISCO, CA, United States 94080

Phone

650-466-7125

Fax

302-655-5049

Executives

Executive Chairman of the Board

Corey Goodman

President, Chief Scientific Officer, Director

Jaume Pons

Chief Executive Officer, Director

Jason Lettmann

Chief Financial Officer, Principal Accounting Officer

Peter Garcia

Senior Vice President - Finance, Chief Accounting Officer

Shelly Pinto